By investing exclusively in the life sciences sector, we’re able to bring singleminded focus and sophisticated understanding to the companies we work with. Our portfolio includes companies based in biotech hotspots as well as under-served, emerging regions across North America, spanning all stages of development.


finding, cultivating, and empowering the most innovative life science companies. we do.


Achillion is a pharmaceutical company developing treatments for patients with challenging infectious diseases – hepatitis C and resistant bacterial infections. It went public in 2006.

learn more »

Aclara Biosciences went public in 2000, powered by innovative microfluidics technology that automated genetic sequencing and other laboratory functions.

learn more »

Pappas Ventures co-founded Afferent in December 2009, after recognizing a novel mechanism with high potential in the treatment of chronic pain and other areas of substantial medical need.

learn more »

Anthera is developing and commercializing novel therapeutics to treat serious human illnesses associated with inflammation. It went public in 2010.

learn more »

Arena made its debut as a public company in 2000, with a focus (then and now) on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs).

learn more »

ArgoMed developed a proprietary, water-induced thermotherapy device and technique to address the non-surgical treatment of benign prostatic hyperplasia (BPH).

learn more »

Athersys is a biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease areas based on a stem cell platform called MultiStem®.

learn more »

Balance Therapeutics is a clinical-stage biopharmaceutical company focused on improving cognitive abilities in patients with intellectual disabilities.

learn more »

BaroSense is a medical device company developing minimally invasive devices for the treatment of obesity, the largest global chronic disease in adults.

learn more »

The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance.

learn more »

BioSyntech focused on biotherapeutic thermogels for regenerative medicine.

learn more »

BrainCells (BCI) is a neurogenesis-based drug discovery and development company targeting novel therapeutics for depression, mood disorders and other central nervous system diseases.

learn more »

Calyx Therapeutics was acquired by Theracos in 2003.

learn more »

CardioDx is a molecular diagnostics company commercializing tools to assist cardiologists in the diagnosis of cardiovascular disease.

learn more »

CeNeRx focused on developing treatments for diseases of the central nervous system.

learn more »

Cequent Pharmaceuticals was acquired by Marina Biotech in 2010.

learn more »

Cerexa was acquired by Forest Laboratories in 2007.

learn more »

Chimerix is developing a range of oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. It went public in April 2013.

learn more »

Cognetix explored the use of snail toxins for the treatment of epilepsy, pain and anesthesia.

learn more »

CoLucid is a clinical stage company developing therapeutics intended for migraine patients who don’t respond well, or at all, to triptan-based drugs.

learn more »

Developed drugs for irritable bowel syndrome and other gastrointestinal disorders.

learn more »

EBM Solutions was acquired by HealthGate Data Corp. in 2003.

learn more »

Elitra’s assets were acquired by Merck in 2004.

learn more »

Emerald is dedicated to the development of naturally occurring biochemicals for crop enhancement.

learn more »

Envisia focuses on the development of novel ocular therapies.

learn more »

FlowCardia was acquired by C. R. Bard in 2010.

learn more »

Gentis develops novel, biomaterials-based products intended to treat spinal disc disease.

learn more »

IlluminOss has developed a groundbreaking, minimally invasive orthopedic system for the stabilization and treatment of bone fractures.

learn more »

LEAD was acquired by BioMarin Pharmaceutical in 2010.

learn more »

LipoScience is building out personalized diagnostic tests for a range of metabolic and other diseases. The company went public in January 2013.

learn more »

Liquidia Technologies uses novel nanoparticle technology platforms to develop innovative healthcare products.

learn more »

Lumena, which was acquired by Shire plc in June 2014, is developing oral therapeutics for adults and children suffering from rare and debilitating liver diseases.

learn more »

Marina is developing and commercializing therapeutic products for rare diseases based on RNA interference (RNAi).

learn more »

Milestone Pharmaceuticals is a cardiovascular drug development company focused on the treatment of transient cardiovascular conditions such as supraventricular tachycardia.

learn more »

Mirati is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer.

learn more »

Nereus utilized specialized research out of the Scripps Institution of Oceanography.

learn more »

NuVasive’s broad suite of minimally invasive products covers the breadth of the spine market. NuVasive went public in 2004.

learn more »

In 2010 Optherion entered into a diagnostic alliance with Sequenom and licensed its technology for therapeutic applications to Baxter.

learn more »

Panacos went public via a reverse merger with V.I. Technologies in 2005.

learn more »

Peninsula Pharmaceuticals was acquired by Johnson & Johnson in 2005.

learn more »

Plexigen focused on instrumentation and service for genetic and proteomic testing.

learn more »

Daiichi Sankyo acquired Plexxikon in 2011 for $935 million.

learn more »

Reprogenesis merged with Ontogeny and Creative BioMolecules to form Curis in 2000.

learn more »

Rotation Medical has developed a proprietary, minimally invasive rotator cuff implant system for the treatment of rotator cuff disease.

learn more »

Selventa is delivering personalized medicine through computational systems biology for drug discovery and development.

learn more »

Sensys focused on advancing technology for non-invasive blood glucose monitoring.

learn more »

Signase assets were acquired by Systems Medicine Inc. in 2005.

learn more »

Spherics developed an oral delivery technology platform.

learn more »

Syndax is a late stage oncology company using epigenetics, a novel way to control gene regulation, to overcome the problem of resistance seen with oncology treatments.

learn more »

Syntonix was acquired by Biogen Idec in 2007.

learn more »

TargeGen was acquired by Sanofi-Aventis in 2010.

learn more »

TESARO is an oncology-focused biopharmaceutical company developing and providing safer and more effective therapeutics and supportive care products. It went public in 2012.

learn more »

Thrasos is a clinical stage therapeutics company discovering and developing targeted therapies for the prevention and treatment of kidney disease.

learn more »

TYRX, which was acquired by Medtronic, Inc. in early 2014, develops and sells implantable, combination drug and device products using novel biomaterials with a wide variety of clinical applications.

learn more »

Ultragenyx is dedicated to life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases. It went public in January 2014.

learn more »

Variagenics went public in 2000 (Nasdaq) and merged into Hyseq in 2002.

learn more »

Exelixis acquired X-Ceptor in 2004.

learn more »